

Docket No.: 61190(50221)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Simon McEwen

Application No.: 10/820,099

Confirmation No.: 8281

Filed: April 7, 2004

Art Unit: 1651

For: THERAPEUTIC COMPOSITION FOR
AUTOIMMUNE CONDITIONS

Examiner: S. M. Hanley

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. Further to Examiner Hanley's telephone conversation of August 11, 2008, with Applicant's agent, Melissa Hunter-Ensor (Registration No. 55,289), it is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicant thanks Examiner Hanley for considering the references in this Supplemental Information Disclosure Statement filed after the mailing of a Final Office Action.

This Supplemental Information Disclosure Statement is filed after the mailing date of a Final Office Action, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant hereby petitions that the Supplemental Information Disclosure Statement be considered.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 61190(50221). A duplicate copy of this paper is enclosed.

Dated: August 12, 2008

Respectfully submitted,

By 
Elbert Chiang, Ph.D.

Registration No.: 60,325

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5502

Attorneys/Agents For Applicant